Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vysis files for approval of breast cancer gene test:

This article was originally published in Clinica

Executive Summary

Genetic analysis firm Vysis has filed a premarket approval application with the FDA to market a test for the HER-2 breast cancer gene. In large quantities, HER-2 is associated with aggressive, difficult-to-treat cancer and a poor prognosis. Vysis test, called PathVysion, is a DNA probe kit which will be used with fluorescence in situ hybridisation, a technique in which DNA probes are labelled with a fluorescent marker which can be detected when the probe binds to the target gene. Vysis' test includes a second probe which is specific for chromosome 17, where the HER-2 gene resides. Vysis is based in Downers Grove, Illinois.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts